GLP1R and type 2 diabetes mellitus: Since the FDA mandate in 2008 to demonstrate cardiovascular safety for new glucose-lowering agents, a series of large randomized cardiovascular outcome trials have evaluated GLP-1 RAs in patients with T2DM, many of whom had established atherosclerotic cardiovascular disease (ASCVD) or multiple risk factors.